Showing results (181-190 of 223) with videos related to
Sort By:
Pageof 23
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2025
Phase 1 and 2 Clinical Studies of the STING Agonist Ulevostinag With and Without Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors or LymphomasKevin J Harrington, Stephane Champiat, Joshua D Brody, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 23, 2012
Patient selection for oncology phase I trials: a multi-institutional study of prognostic factorsDavid Olmos, Roger P A'hern, Silvia Marsoni, et al.JCO Precision Oncology|September 11, 2020
Exploitation of Precision Medicine Trials Data: Examples of Long Responders From the SHIVA01 TrialClémence Basse, Claire Morel, Céline Callens, et al.Cell Reports. Medicine|February 11, 2025
Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancersStephane Champiat, Elena Garralda, Vladimir Galvao, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 25, 2019
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 StudiesHyun Cheol Chung, Sarina A Piha-Paul, Jose Lopez-Martin, et al.The Lancet. Oncology|September 13, 2020
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 studyAurélien Marabelle, Marwan Fakih, Juanita Lopez, et al.Cancers|June 22, 2023
Development and External Validation of a PET Radiomic Model for Prognostication of Head and Neck CancerWyanne A Noortman, Nicolas Aide, Dennis Vriens, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 26, 2014
Dose-response relationship in phase i clinical trials: a European Drug Development Network (EDDN) Collaboration StudyVictor Moreno García, David Olmos, Carlos Gomez-Roca, et al.The Lancet. Gastroenterology & Hepatology|February 3, 2022
Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 studyAurelien Marabelle, Philippe A Cassier, Marwan Fakih, et al.Cancers|July 14, 2023
Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib CohortOlivier Trédan, Maud Toulmonde, Christophe Le Tourneau, et al.Pageof 23